Week in Review: $1.5 Billion Total in Week's China Deals

Deals and Financings   Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop eight assets in-licensed for China development; Genor Biopharma of Shanghai raised $371 million in its Hong Kong IPO and rose 22%, giving the company a market capitalization of $1.8 billion; 10x Genomics will pay $350 million to acquire Decheng-backed ReadCoor, a Boston developer of spatial-onomics sequencing devices; Hinova, a Chengdu novel drug biopharma, closed a $147 million Series C round for nine assets including treatments for prostate cancer and gout; Corvus Pharma formed a China subsidiary, Angel Pharma, with a $106 million valuation to develop its assets in China ; Creative Biosciences, a Guangzhou oncology testing company, raised $90 million for diagnostic products, including a stool-based test for colon cancer; Guangzhou Link Health and Shenzhen Pregene announced a $65 million deal to acquire China/Asia rights to a cell therapy for bone fractures; Covid-19 Pandemic Junshi Bio of Shanghai and Lilly released positive interim data from a Phase II trial of their paired COVID-19 antibody treatment; Fosun Pharma was granted US FDA approval to begin clinical tests of its investigational COVID-19 antibody treatment; Trials and Approvals   Harbour BioMed, a China-US biopharma, began a China Phase II trial of a treatment for myasthenia gravis and adult immune thrombocytopenia; Zai Lab of Shanghai dosed the first patient in a China Phase III trial of a PD-1 antibody in first-line NSCLC; Shanghai 's CARsgen Therapeutics was granted orphan drug designation in the US for its anti-claudin18.2 CAR-T candidate in patients with gastric adenocarcinoma. Stock Symbols: (HK:1952) (HK: 6998) (NSDQ: TXG) (NSDQ: CRVS) (HK: 1877; SHA: 688180) (NYSE: LLY) (SHA: 600196; HK: 02196) (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.